711 related articles for article (PubMed ID: 30197282)
21. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
Sricharoenchai S; Sirivichayakul C; Chokephaibulkit K; Pitisuttithum P; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chinwangso P; Poredi IK; Petre J; Thai PH; Viviani S
Lancet Infect Dis; 2018 Jan; 18(1):58-67. PubMed ID: 29066131
[TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of an indigenously developed tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine (Tdap) in adults, adolescents, and children in India.
Sharma HJ; Parekh S; Pujari P; Shewale S; Desai S; Kawade A; Ravi M; Oswal J; James S; Mahantashetti N; Munshi R; Ghosh A; Rao V; Balsubramaniam S; Varughese P; Somshekhar A; Ginsburg AS; Rao H; Gautam M; Gairola S; Shaligram U
Expert Rev Vaccines; 2023; 22(1):278-287. PubMed ID: 36883291
[TBL] [Abstract][Full Text] [Related]
23. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged ≥50 years: A randomized trial.
Strezova A; Lal H; Enweonye I; Campora L; Beukelaers P; Segall N; Heineman TC; Schuind AE; Oostvogels L
Vaccine; 2019 Sep; 37(39):5877-5885. PubMed ID: 31443993
[TBL] [Abstract][Full Text] [Related]
24. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial.
Scheifele DW; Halperin SA; Ochnio JJ; Ferguson AC; Skowronski DM
Pediatr Infect Dis J; 2005 Dec; 24(12):1059-66. PubMed ID: 16371866
[TBL] [Abstract][Full Text] [Related]
25. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.
Weston WM; Friedland LR; Wu X; Howe B
Vaccine; 2012 Feb; 30(9):1721-8. PubMed ID: 22212127
[TBL] [Abstract][Full Text] [Related]
26. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine.
Tomovici A; Barreto L; Zickler P; Meekison W; Noya F; Voloshen T; Lavigne P
Vaccine; 2012 Mar; 30(16):2647-53. PubMed ID: 22353673
[TBL] [Abstract][Full Text] [Related]
27. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).
Dhillon S
BioDrugs; 2010 Oct; 24(5):299-302. PubMed ID: 20795752
[TBL] [Abstract][Full Text] [Related]
28. Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine.
Weston W; Messier M; Friedland LR; Wu X; Howe B
Vaccine; 2011 Nov; 29(47):8483-6. PubMed ID: 21945698
[TBL] [Abstract][Full Text] [Related]
29. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
Zepp F; Knuf M; Habermehl P; Mannhardt-Laakmann W; Howe B; Friedland LR
J Pediatr; 2006 Nov; 149(5):603-610. PubMed ID: 17095328
[TBL] [Abstract][Full Text] [Related]
30. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel.
Kretsinger K; Broder KR; Cortese MM; Joyce MP; Ortega-Sanchez I; Lee GM; Tiwari T; Cohn AC; Slade BA; Iskander JK; Mijalski CM; Brown KH; Murphy TV; ; ;
MMWR Recomm Rep; 2006 Dec; 55(RR-17):1-37. PubMed ID: 17167397
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine dose in healthy Russian participants: a phase III, open-label study.
Asatryan A; Meyer N; Scherbakov M; Romanenko V; Osipova I; Galustyan A; Shamsheva O; Latysheva T; Myasnikova T; Baudson N; Dodet M; Xavier S; Harrington L; Kuznetsova A; Campora L; Van den Steen P
Hum Vaccin Immunother; 2021 Mar; 17(3):723-730. PubMed ID: 32845735
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(®)) in adults 55 years of age and over: a sub-analysis of four trials.
Van Damme P; McIntyre P; Grimprel E; Kuriyakose S; Jacquet JM; Hardt K; Messier M; Van Der Meeren O
Vaccine; 2011 Aug; 29(35):5932-9. PubMed ID: 21718738
[TBL] [Abstract][Full Text] [Related]
33. Reduced-antigen, combined diphtheria-tetanus-acellular pertussis vaccine, adsorbed (Boostrix) US formulation): use as a single-dose booster immunization in adolescents aged 10-18 years.
Frampton JE; Keam SJ
Paediatr Drugs; 2006; 8(3):189-95; discussion 196. PubMed ID: 16774298
[TBL] [Abstract][Full Text] [Related]
34. Tdap5 vaccine (Covaxis): a review of its use as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged 4 years), adolescents, and adults.
Scott LJ
BioDrugs; 2010 Dec; 24(6):387-406. PubMed ID: 21043546
[TBL] [Abstract][Full Text] [Related]
35. Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women.
Fortner KB; Swamy GK; Broder KR; Jimenez-Truque N; Zhu Y; Moro PL; Liang J; Walter EB; Heine RP; Moody MA; Yoder S; Edwards KM
Vaccine; 2018 Oct; 36(42):6354-6360. PubMed ID: 30219367
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations.
Schmitt HJ; Zepp F; Müschenborn S; Sümenicht G; Schuind A; Beutel K; Knuf M; Bock HL; Bogaerts H; Clemens R
Eur J Pediatr; 1998 Mar; 157(3):208-14. PubMed ID: 9537487
[TBL] [Abstract][Full Text] [Related]
38. Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine (Boostrix): a review of its use as a single-dose booster immunization.
Frampton JE; Keating GM
BioDrugs; 2006; 20(6):371-89. PubMed ID: 17176125
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study.
John T; Voysey M; Yu LM; McCarthy N; Baudin M; Richard P; Fiquet A; Kitchin N; Pollard AJ
Vaccine; 2015 Aug; 33(36):4579-85. PubMed ID: 26165918
[TBL] [Abstract][Full Text] [Related]
40. Quantity and Quality of Antibodies After Acellular Versus Whole-cell Pertussis Vaccines in Infants Born to Mothers Who Received Tetanus, Diphtheria, and Acellular Pertussis Vaccine During Pregnancy: A Randomized Trial.
Wanlapakorn N; Maertens K; Vongpunsawad S; Puenpa J; Tran TMP; Hens N; Van Damme P; Thiriard A; Raze D; Locht C; Poovorawan Y; Leuridan E
Clin Infect Dis; 2020 Jun; 71(1):72-80. PubMed ID: 31418814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
